Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2012 1
2013 1
2016 3
2017 6
2018 4
2019 5
2020 2
2021 4
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Serum biomarkers for diagnosis and characterization of prostate cancer.
Gómez Gómez E, Puche Sanz I, Valero Rosa J, Carrasco Valiente J, Campos Hernandez JP, Anglada Curado FJ. Gómez Gómez E, et al. Among authors: carrasco valiente j. Arch Esp Urol. 2022 Mar;75(2):156-164. Arch Esp Urol. 2022. PMID: 35332885 Free article. Review. English, Spanish.
Mass Spectrometry-Based Biomarkers to Detect Prostate Cancer: A Multicentric Study Based on Non-Invasive Urine Collection without Prior Digital Rectal Examination.
Frantzi M, Culig Z, Heidegger I, Mokou M, Latosinska A, Roesch MC, Merseburger AS, Makridakis M, Vlahou A, Blanca-Pedregosa A, Carrasco-Valiente J, Mischak H, Gomez-Gomez E. Frantzi M, et al. Among authors: carrasco valiente j. Cancers (Basel). 2023 Feb 11;15(4):1166. doi: 10.3390/cancers15041166. Cancers (Basel). 2023. PMID: 36831508 Free PMC article.
The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer.
Hormaechea-Agulla D, Jiménez-Vacas JM, Gómez-Gómez E, L-López F, Carrasco-Valiente J, Valero-Rosa J, Moreno MM, Sánchez-Sánchez R, Ortega-Salas R, Gracia-Navarro F, Culler MD, Ibáñez-Costa A, Gahete MD, Requena MJ, Castaño JP, Luque RM. Hormaechea-Agulla D, et al. Among authors: carrasco valiente j. FASEB J. 2017 Nov;31(11):4682-4696. doi: 10.1096/fj.201601264RRR. Epub 2017 Jul 13. FASEB J. 2017. PMID: 28705809
Telomere-based risk models for the early diagnosis of clinically significant prostate cancer.
Rubio Galisteo JM, Fernández L, Gómez Gómez E, de Pedro N, Cano Castiñeira R, Pedregosa AB, Guler I, Carrasco Valiente J, Esteban L, González S, Castelló N, Otero L, García J, Segovia E, Requena Tapia MJ, Najarro P. Rubio Galisteo JM, et al. Among authors: carrasco valiente j. Prostate Cancer Prostatic Dis. 2021 Mar;24(1):88-95. doi: 10.1038/s41391-020-0232-4. Epub 2020 May 4. Prostate Cancer Prostatic Dis. 2021. PMID: 32367011 Free PMC article.
CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer.
Frantzi M, Gomez Gomez E, Blanca Pedregosa A, Valero Rosa J, Latosinska A, Culig Z, Merseburger AS, Luque RM, Requena Tapia MJ, Mischak H, Carrasco Valiente J. Frantzi M, et al. Among authors: carrasco valiente j. Br J Cancer. 2019 Jun;120(12):1120-1128. doi: 10.1038/s41416-019-0472-z. Epub 2019 May 16. Br J Cancer. 2019. PMID: 31092909 Free PMC article.
In1-Ghrelin Splicing Variant as a Key Element in the Pathophysiological Association Between Obesity and Prostate Cancer.
Jiménez-Vacas JM, Montero-Hidalgo AJ, Gómez-Gómez E, Fuentes-Fayos AC, Ruiz-Pino F, Guler I, Camargo A, Anglada FJ, Carrasco-Valiente J, Tena-Sempere M, Sarmento-Cabral A, Castaño JP, Gahete MD, Luque RM. Jiménez-Vacas JM, et al. Among authors: carrasco valiente j. J Clin Endocrinol Metab. 2021 Nov 19;106(12):e4956-e4968. doi: 10.1210/clinem/dgab516. J Clin Endocrinol Metab. 2021. PMID: 34255835
Hand metastasis from renal carcinoma.
Anglada-Curado FJ, De Haro-Padilla J, Carrasco-Valiente J, Alvarez-Kindelan J, Ruiz-Garcia J, Requena-Tapia MJ. Anglada-Curado FJ, et al. Among authors: carrasco valiente j. Urology. 2010 Oct;76(4):846. doi: 10.1016/j.urology.2009.11.035. Epub 2010 Feb 6. Urology. 2010. PMID: 20138337
Dysregulation of the miRNome unveils a crosstalk between obesity and prostate cancer: miR-107 asa personalized diagnostic and therapeutic tool.
Herrero-Aguayo V, Sáez-Martínez P, Jiménez-Vacas JM, Moreno-Montilla MT, Montero-Hidalgo AJ, Pérez-Gómez JM, López-Canovas JL, Porcel-Pastrana F, Carrasco-Valiente J, Anglada FJ, Gómez-Gómez E, Yubero-Serrano EM, Ibañez-Costa A, Herrera-Martínez AD, Sarmento-Cabral A, Gahete MD, Luque RM. Herrero-Aguayo V, et al. Among authors: carrasco valiente j. Mol Ther Nucleic Acids. 2022 Feb 12;27:1164-1178. doi: 10.1016/j.omtn.2022.02.010. eCollection 2022 Mar 8. Mol Ther Nucleic Acids. 2022. PMID: 35282415 Free PMC article.
The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness.
Hormaechea-Agulla D, Gahete MD, Jiménez-Vacas JM, Gómez-Gómez E, Ibáñez-Costa A, L-López F, Rivero-Cortés E, Sarmento-Cabral A, Valero-Rosa J, Carrasco-Valiente J, Sánchez-Sánchez R, Ortega-Salas R, Moreno MM, Tsomaia N, Swanson SM, Culler MD, Requena MJ, Castaño JP, Luque RM. Hormaechea-Agulla D, et al. Among authors: carrasco valiente j. Mol Cancer. 2017 Aug 29;16(1):146. doi: 10.1186/s12943-017-0713-9. Mol Cancer. 2017. PMID: 28851363 Free PMC article.
24 results